जहाँ विज्ञान है जीवन की सेवा में, वहाँ होता है स्वस्थ भविष्य का निर्माण – Laurus Labs के साथ आप हमेशा सुरक्षित!

Technical Analysis (Oct 2025) •CMP: ₹900.05

•The stock is showing momentum recovery after previous consolidation; recent price breakout above moving averages (green/cyan/blue/black/gold lines) confirms bullish undertone. •Parabolic SAR: Flipped below price – bullish indicator. •MACD: Crossed positive with rising histogram, suggesting fresh upward power. •RSI(14): At 59, healthy but not yet overbought, signaling trend strength. •Support: ₹865–₹870 first zone, ₹840 strong base; Resistance: ₹915–₹940 immediate, ₹955–₹970 stretch targets. • Volume and sentiment favor buyers; if ₹870 sustains, structure is positive, otherwise risk of pullback increases. _ Result Trend & Future Outlook •Q1 & Q2 FY26 results reflect a sharp rebound in profit and margin expansion, led by operational leverage and specialty pipeline. • Management is targeting 50% revenue share from high-margin CDMO and innovative therapies by 2027; capex guidance indicates aggressive scaling. •Improved mix, operational efficiency, and asset utilization raise FY27E margin/income projections, but premium valuation requires sustained delivery. •Near term, any new international contract/joint venture or USFDA approval can act as sentiment boosters; conversely, adverse regulatory/currency moves could trigger volatility. Entry, Target, and Risk Management •! Buy on dips between ₹870–₹900, keeping a closing stop loss at ₹840. •Short-term targets: ₹915 & ₹940. On breakout and strength, look for ₹955–₹970. •Long-term holders may use corrections to accumulate, subject to fundamental strength and macro cues. •The uptrend will be valid as long as ₹870 support holds; break below this can invite profit booking.